Literature DB >> 9712426

Müllerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors.

X Matias-Guiu1, C Pons, J Prat.   

Abstract

Müllerian inhibiting substance (MIS), alpha-inhibin, and CD99 are expressed by normal and neoplastic sex cord and stromal gonadal derivatives. The expression of MIS, inhibin, and CD99 was evaluated by immunohistochemistry in a series of 19 sex cord-stromal tumors and seven ovarian endometrioid carcinomas resembling sex cord-stromal tumors. Normal ovaries and testes from patients with the androgen insensitivity syndrome were used as control. All three markers were detected in primordial ovarian follicles and immature seminiferous tubules. Both inhibin and MIS were expressed by all sex cord-stromal tumors, but inhibin immunostaining appeared stronger and more diffusely distributed. CD99 was expressed by all adult and juvenile granulosa cell tumors, but only focally by Sertoli-Leydig cell tumors. In Sertoli-Leydig cell tumors, the three markers were predominantly expressed by the Sertoli cells. None of the seven endometrioid carcinomas with a sex cord-stromal pattern was positive for MIS or inhibin; two of them reacted for CD99, but their staining patterns were not membranous. Inhibin immunoreactivity was also detected in foci of stromal luteinization, occasionally present in these tumors. MIS, inhibin, and CD99 are potentially useful markers in the differential diagnosis between sex cord-stromal tumors and endometrioid carcinomas resembling sex cord-stromal tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712426     DOI: 10.1016/s0046-8177(98)90454-3

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Expression of CD99 in pleomorphic carcinomas of the lung.

Authors:  Seong-Ho Yoo; Jungho Han; Tae Jin Kim; Doo Hyun Chung
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

2.  Endocrine pathology of the ovary : in tribute to Robert E Scully, MD.

Authors:  Esther Oliva; Robert H Young
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

3.  Uterine tumour resembling ovarian sex cord tumour is an immunohistochemically polyphenotypic neoplasm which exhibits coexpression of epithelial, myoid and sex cord markers.

Authors:  D P Hurrell; W G McCluggage
Journal:  J Clin Pathol       Date:  2006-12-20       Impact factor: 3.411

Review 4.  Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms.

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

Review 5.  Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Authors:  Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2017-06-22       Impact factor: 3.412

6.  Non-Leydig sex-cord tumors of the testis. The place of immunohistochemistry in diagnosis and prognosis. A study of twenty cases.

Authors:  Eva Compérat; Fréderique Tissier; Karine Boyé; Gonzague De Pinieux; Annick Vieillefond
Journal:  Virchows Arch       Date:  2004-04-16       Impact factor: 4.064

7.  [Immunohistochemical sex cord markers. Description and use in the differential diagnosis of ovarian tumors].

Authors:  F Kommoss; D Schmidt
Journal:  Pathologe       Date:  2007-05       Impact factor: 1.011

8.  Precocious puberty secondary to a mixed germ cell-sex cord-stromal tumor associated with an ovarian yolk sac tumor: a case report.

Authors:  Kotb Abbass Metwalley; Dalia Ahmed Elsers; Hekma Saad Farghaly; Hanaa Abdel-Lateif; Mohamed Abdel-Kader
Journal:  J Med Case Rep       Date:  2012-06-26

9.  Retiform Sertoli-Leydig Cell Tumor in a 38-Year-Old Woman: A Case Report, Retrospective Review, and Review of Current Literature.

Authors:  Laura C Nwogu; Josh A Showalter; Suvra Roy; Michael T Deavers; Bihong Zhao
Journal:  Case Rep Pathol       Date:  2017-02-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.